Walvax Biotechnology Co., Ltd.

Equities

300142

CNE100000WN2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
15.45 CNY -3.80% Intraday chart for Walvax Biotechnology Co., Ltd. -13.01% -34.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit MT
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023. CI
Lanvin Group Chief Executive Joann Cheng Steps Down MT
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3% MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023. CI
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Walvax Biotechnology's COVID-19 Vaccine Clinical Trial Results Show Efficacy, Safety MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023. CI
Walvax Biotechnology Chairman, Affiliates Complete Purchase of 101 Million Yuan Shares MT
Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023 CI
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2022 CI
Walvax Biotechnology Co., Ltd. announces an Equity Buyback for 4,000,000 shares, for CNY 200 million. CI
Walvax Biotechnology Co., Ltd. authorizes a Buyback Plan. CI
Walvax Biotechnology Co., Ltd. Proposes Cash Dividend for 2022 CI
Walvax Biotechnology Gets Patent for Freeze-Drying System for Vaccines MT
China mRNA vaccine development jumps into high gear RE
Jiangsu Yiming Rongyao Medical Technology Co., Ltd agreed to acquire Jiangsu Walvax Biotechnology Co., Ltd. from Walvax Biotechnology Co., Ltd. and Guangzhou Jiahe Biotechnology Co. Ltd. for CNY 290 million. CI
Walvax Biotechnology Chairman Plans Boosting Stake MT
Walvax Biotechnology Gets Approval For Third Phase Trial Into COVID-19 Vaccine MT
Chart Walvax Biotechnology Co., Ltd.
More charts
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
15.45 CNY
Average target price
22 CNY
Spread / Average Target
+42.39%
Consensus